Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander hoofdstuk

2011 | OriginalPaper | Hoofdstuk

6. Cardiovasculair Risicomanagement Bij Vrouwen

Auteurs: Dr. Angela Maas, Dr. Ed De Kluiver, Prof. Dr. Toine Lagro-Janssen

Gepubliceerd in: Handboek gynaecardiologie

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Een gezonde leefstijl is de basis voor preventie van alle cardiovasculaire ziekten (CVZ). Meer dan 10 jaar geleden werd in de Nurses’ Health Studie al aangetoond dat hiermee meer dan 80% van alle cardiovasculaire gebeurtenissen bij vrouwen te voorkomen is.1 De veranderingen in leefstijl in onze westerse samenleving wijzen echter op een tegenovergestelde ontwikkeling met een verschuiving van het cardiovasculaire risico bij vrouwen van oudere naar meer middelbare leeftijd.2 Daarbij krijgen vrouwen vaker een CVA dan een acuut coronair syndroom (ACS), terwijl dit bij mannen juist omgekeerd is (zie figuur 2.2). In de EUROASPIRE III-studie werd in het afgelopen decennium bij vrouwen een sterke toename gezien van obesitas en diabetes mellitus en viel op dat vooral jonge vrouwen (< 50 jaar) meer zijn gaan roken.3 Vrouwen bleken na een doorgemaakte cardiovasculaire gebeurtenis minder goed de streefwaarden te bereiken van bloeddruk- en cholesterolwaarden dan mannen. Hoewel het meeste onderzoek naar evidence-based medicatie voor de preventie van CVZ van oudsher gedaan is in mannelijke cohorten, bevestigen ook andere studies dat vrouwen nog steeds worden onderbehandeld.47 Dit draagt bij aan de hogere mortaliteit na een ACS en CVA. Ook ten aanzien van primaire preventie leeft nog sterk de perceptie dat het ‘bij vrouwen allemaal wel meevalt’.8 Terwijl de sterfte aan CVZ niet alleen landelijk, maar ook wereldwijd groter is bij vrouwen dan bij mannen, wordt hiermee voorbijgegaan aan de grotere ziektelast en verlies aan kwaliteit van leven die dit bij vrouwen op oudere leeftijd met zich meebrengt.9
Literatuur
1.
go back to reference Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343: 16–22. PubMedCrossRef Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343: 16–22. PubMedCrossRef
2.
go back to reference Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med 2009; 169; 1762-66. PubMedCrossRef Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med 2009; 169; 1762-66. PubMedCrossRef
3.
go back to reference Dallongeville J, De Bacquer D, Heidrich J, De Backer G, Prugger C, Kotseva K, et al. Euroaspire Study Group. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event. Heart 2010; 96: 1744–49. CrossRef Dallongeville J, De Bacquer D, Heidrich J, De Backer G, Prugger C, Kotseva K, et al. Euroaspire Study Group. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event. Heart 2010; 96: 1744–49. CrossRef
4.
go back to reference Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 2010; 3: 135–42. PubMedCrossRef Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 2010; 3: 135–42. PubMedCrossRef
5.
go back to reference Stramba-Badiale M. Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. Eur Heart J 2010; 31: 1677–81. CrossRef Stramba-Badiale M. Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. Eur Heart J 2010; 31: 1677–81. CrossRef
6.
go back to reference Bugiardini R, Yan AT, Yan RT, et al. Factors influencing underutilization of evidence-based therapies in women. European Heart Journal 2011; 32: 1337–44. PubMedCrossRef Bugiardini R, Yan AT, Yan RT, et al. Factors influencing underutilization of evidence-based therapies in women. European Heart Journal 2011; 32: 1337–44. PubMedCrossRef
7.
go back to reference Johnston N, Schenck-Gustafsson K, Lagerqvist B. Are we using cardiovascular medications and coronary angiography appropriately in men and women with chest pain? Eur Heart J 2011: 32: 1331-36. PubMedCrossRef Johnston N, Schenck-Gustafsson K, Lagerqvist B. Are we using cardiovascular medications and coronary angiography appropriately in men and women with chest pain? Eur Heart J 2011: 32: 1331-36. PubMedCrossRef
8.
go back to reference Bairey Merz CN. The Yentl syndrome is alive and well. Eur Heart J 2011; 32: 1313–15. CrossRef Bairey Merz CN. The Yentl syndrome is alive and well. Eur Heart J 2011; 32: 1313–15. CrossRef
9.
go back to reference Maas AHEM, Schouw YT van der, Regitz-Zagrosek V, Swahn E, Appelman YT, Pasterkamp G, et al. Red alert for women’s heart: the urgent need for more research and knowledge on cardiovascular disease in women. Eur Heart J 2011; 32: 1362–68. PubMedCrossRef Maas AHEM, Schouw YT van der, Regitz-Zagrosek V, Swahn E, Appelman YT, Pasterkamp G, et al. Red alert for women’s heart: the urgent need for more research and knowledge on cardiovascular disease in women. Eur Heart J 2011; 32: 1362–68. PubMedCrossRef
10.
go back to reference Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005; 111: 499-510. PubMedCrossRef Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005; 111: 499-510. PubMedCrossRef
11.
go back to reference Mosca L, Mochari-Greenberger H, Dolor RJ, Newby LK, Robb KJ. Twelve-year follow-up of american women’s awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes 2010; 3: 120–27. PubMedCrossRef Mosca L, Mochari-Greenberger H, Dolor RJ, Newby LK, Robb KJ. Twelve-year follow-up of american women’s awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes 2010; 3: 120–27. PubMedCrossRef
12.
go back to reference Diercks DB, Owen KP, Kontos MC, Blomkalns A, Chen AY, Miller C, et al. Gender differences in time to presentation for myocardial infarction before and after a national women’s cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation (crusade) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (ncdr action Registry-gwtg). Am Heart J 2010; 160: 80–87. PubMedCrossRef Diercks DB, Owen KP, Kontos MC, Blomkalns A, Chen AY, Miller C, et al. Gender differences in time to presentation for myocardial infarction before and after a national women’s cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation (crusade) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (ncdr action Registry-gwtg). Am Heart J 2010; 160: 80–87. PubMedCrossRef
13.
go back to reference Lloyd-Jones DM, Leip EP, Larson MG, D’Agostino RB, Beiser A, Wilson PW, et al. Prediction of life-time risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113; 791-98. PubMedCrossRef Lloyd-Jones DM, Leip EP, Larson MG, D’Agostino RB, Beiser A, Wilson PW, et al. Prediction of life-time risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113; 791-98. PubMedCrossRef
14.
go back to reference Cooney MT, Dudina AL, Graham IA. Value and limitations of existing scores for the assessment of cardiovascular risk. J Am Coll Cardiol 2009; 54: 1209-27. PubMedCrossRef Cooney MT, Dudina AL, Graham IA. Value and limitations of existing scores for the assessment of cardiovascular risk. J Am Coll Cardiol 2009; 54: 1209-27. PubMedCrossRef
15.
go back to reference Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998; 316: 1043–47. PubMedCrossRef Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998; 316: 1043–47. PubMedCrossRef
16.
go back to reference Regitz-Zagrosek V, Lehmkuhl E, Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med 2007; 4 (suppl): S162-77. PubMedCrossRef Regitz-Zagrosek V, Lehmkuhl E, Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med 2007; 4 (suppl): S162-77. PubMedCrossRef
17.
go back to reference Roger VL, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, et al. Heart disease and stroke statistics update: a report from the American Heart Association. Circulation 2011; 123: e18-e209. PubMedCrossRef Roger VL, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, et al. Heart disease and stroke statistics update: a report from the American Heart Association. Circulation 2011; 123: e18-e209. PubMedCrossRef
19.
go back to reference Lloyd-Jones DM. Cardiovascular risk prediction. Basic concepts, current status and future directions. Circulation 2010; 121: 1768–77. PubMedCrossRef Lloyd-Jones DM. Cardiovascular risk prediction. Basic concepts, current status and future directions. Circulation 2010; 121: 1768–77. PubMedCrossRef
20.
go back to reference Cooney MT, Dudina A, DAgostino RD, Graham IM. Cardiovascular risk-estimation systems in primary prevention. Do they differ? Do they make a difference? Can we see the future? Circulation 2010; 122: 300-10. PubMedCrossRef Cooney MT, Dudina A, DAgostino RD, Graham IM. Cardiovascular risk-estimation systems in primary prevention. Do they differ? Do they make a difference? Can we see the future? Circulation 2010; 122: 300-10. PubMedCrossRef
21.
go back to reference D’Agostino RB Sr, Vasan RS, Pencina MJ, WolfPA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743–53. CrossRef D’Agostino RB Sr, Vasan RS, Pencina MJ, WolfPA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743–53. CrossRef
22.
go back to reference Sillesen H, Falk E. Why not screen for subclinical atherosclerosis? Lancet 2011. doi: 10.1016/S0140-6736(11)60059-7. Sillesen H, Falk E. Why not screen for subclinical atherosclerosis? Lancet 2011. doi: 10.1016/S0140-6736(11)60059-7.
23.
go back to reference Vasan R, Kannel WB. Strategies for cardiovascular risk assessment and prevention over the life course. Progress amid imperfections. Circulation 2009; 120: 360–63. PubMedCrossRef Vasan R, Kannel WB. Strategies for cardiovascular risk assessment and prevention over the life course. Progress amid imperfections. Circulation 2009; 120: 360–63. PubMedCrossRef
24.
go back to reference Marma AK, Lloyd-Jones DM. Systematic examination of the updated Framingham heart study general cardiovascular risk profile. Circulation 2009; 120: 384–90. PubMedCrossRef Marma AK, Lloyd-Jones DM. Systematic examination of the updated Framingham heart study general cardiovascular risk profile. Circulation 2009; 120: 384–90. PubMedCrossRef
25.
go back to reference Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women, 2011 update. A guideline from the American Heart Association. Circulation 2011; 123: 1243–62. PubMedCrossRef Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women, 2011 update. A guideline from the American Heart Association. Circulation 2011; 123: 1243–62. PubMedCrossRef
26.
go back to reference Dekker JM, Alssema M, Janssen PGH, Van der Paardt M, Festen CCS, Van Oosterhout MJW, et al. M96. NHG-Standaard Preventie Consult module Cardiometabool Risico. Huisarts Wet 2011; 54:138-55. CrossRef Dekker JM, Alssema M, Janssen PGH, Van der Paardt M, Festen CCS, Van Oosterhout MJW, et al. M96. NHG-Standaard Preventie Consult module Cardiometabool Risico. Huisarts Wet 2011; 54:138-55. CrossRef
27.
go back to reference Nilsson PM, Boutouyrie P, Laurent S. A tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension 2009; 54: 3–10. PubMedCrossRef Nilsson PM, Boutouyrie P, Laurent S. A tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension 2009; 54: 3–10. PubMedCrossRef
28.
go back to reference Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335: 974–83. PubMedCrossRef Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335: 974–83. PubMedCrossRef
29.
go back to reference Kharazmi E, Dossus L, Rohrmann S, Kaaks R. Pregnancy loss and risk of cardiovascular disease: a prospective population-based cohort study (EPIC-Heidelberg). Heart 2011; 97: 49–54. PubMedCrossRef Kharazmi E, Dossus L, Rohrmann S, Kaaks R. Pregnancy loss and risk of cardiovascular disease: a prospective population-based cohort study (EPIC-Heidelberg). Heart 2011; 97: 49–54. PubMedCrossRef
30.
go back to reference Drost JT, Arpaci G, Ottervanger JP, Boer MJ de, Eyck J van, Schouw YT van der, Maas AHEM. Cardiovascular risk factors in women 10 years post early preeclampsia. The Preeclampsia Risk EValuation in FEMales Study (prevfem) Eur J Cardiovasc Prev Rehabil (in press). Drost JT, Arpaci G, Ottervanger JP, Boer MJ de, Eyck J van, Schouw YT van der, Maas AHEM. Cardiovascular risk factors in women 10 years post early preeclampsia. The Preeclampsia Risk EValuation in FEMales Study (prevfem) Eur J Cardiovasc Prev Rehabil (in press).
31.
32.
go back to reference Gast G-CM, Grobbee DE, Pop VJM, Keyzer JJ, Wijnands-van Gent CJM, Samsioe GN, Nilsson PM, Schouw YT van der. Menopausal complaints are associated with cardio-vascular risk factors. Hypertension 2008; 51: 1492–98. PubMedCrossRef Gast G-CM, Grobbee DE, Pop VJM, Keyzer JJ, Wijnands-van Gent CJM, Samsioe GN, Nilsson PM, Schouw YT van der. Menopausal complaints are associated with cardio-vascular risk factors. Hypertension 2008; 51: 1492–98. PubMedCrossRef
33.
go back to reference Szmuilowicz ED, Manson JE, Rossouw JE, Howard BV, Margolis KL, Greep NC, et al. Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause 2011; 18: 603-10. PubMedCrossRef Szmuilowicz ED, Manson JE, Rossouw JE, Howard BV, Margolis KL, Greep NC, et al. Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause 2011; 18: 603-10. PubMedCrossRef
34.
go back to reference Shaw LJ, Bugiardini R, Bairey Merz CN. Women and ischemic heart disease. Evolving knowledge. J Am Coll Cardiol 2009; 54: 1561–75. PubMedCrossRef Shaw LJ, Bugiardini R, Bairey Merz CN. Women and ischemic heart disease. Evolving knowledge. J Am Coll Cardiol 2009; 54: 1561–75. PubMedCrossRef
35.
go back to reference Banks K, Puttagunta D, Murphy S, Lo M, McGuire DK, Lemos JA de, et al. Clinical characteristics, vascular function and inflammation in women with angina in the absence of coronary atherosclerosis. The Dallas Heart Study. J Am Coll Cardiol Img 2011; 4: 65–73. Banks K, Puttagunta D, Murphy S, Lo M, McGuire DK, Lemos JA de, et al. Clinical characteristics, vascular function and inflammation in women with angina in the absence of coronary atherosclerosis. The Dallas Heart Study. J Am Coll Cardiol Img 2011; 4: 65–73.
36.
go back to reference Gulati M, Cooper-DeHoff RM, McClure C, Johnson D, Shaw LJ, Handberg EM, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease. A report from the Women’s Ischemia Syndrome Evaluation Study and the St James Women take Heart Project. Arch Intern Med 2009; 169: 843–50. PubMedCrossRef Gulati M, Cooper-DeHoff RM, McClure C, Johnson D, Shaw LJ, Handberg EM, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease. A report from the Women’s Ischemia Syndrome Evaluation Study and the St James Women take Heart Project. Arch Intern Med 2009; 169: 843–50. PubMedCrossRef
37.
go back to reference Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94: 483–9. PubMedCrossRef Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94: 483–9. PubMedCrossRef
38.
go back to reference Narkiewicz K, Graniero GR, DÉste D, Mattarei M, Zonzin P, Palatini P. Ambulatory blood pressure in mild hypertensive women taking oral contraceptives. A case-control study. Am J Hypertens 1995; 8: 249–53. PubMedCrossRef Narkiewicz K, Graniero GR, DÉste D, Mattarei M, Zonzin P, Palatini P. Ambulatory blood pressure in mild hypertensive women taking oral contraceptives. A case-control study. Am J Hypertens 1995; 8: 249–53. PubMedCrossRef
39.
go back to reference Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009; 53: 221–31. PubMedCrossRef Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009; 53: 221–31. PubMedCrossRef
40.
go back to reference Kaunitz AM. Clinical practice. Hormonal contraception on women of older reproductive age. N Engl J Med 2008; 358: 1262–70. CrossRef Kaunitz AM. Clinical practice. Hormonal contraception on women of older reproductive age. N Engl J Med 2008; 358: 1262–70. CrossRef
41.
go back to reference Merz CN, Johnson BD, Berga S, Braunstein G, Reis SE, Bittner V. Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the national Heart, Lung and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation. Fertil Steril 2006; 85: 1425–31. PubMedCrossRef Merz CN, Johnson BD, Berga S, Braunstein G, Reis SE, Bittner V. Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the national Heart, Lung and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation. Fertil Steril 2006; 85: 1425–31. PubMedCrossRef
42.
go back to reference Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension. An age-old debate. Hypertension 2008; 51: 952–59. PubMedCrossRef Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension. An age-old debate. Hypertension 2008; 51: 952–59. PubMedCrossRef
43.
go back to reference Conen D, Ridker PM, Mora S, Buring JE, Glynn RJ. Blood pressure and risk of developing type 2 diabetes mellitus: The Women’s Health Study. Eur Heart J 2007; 28: 2937–43. PubMedCrossRef Conen D, Ridker PM, Mora S, Buring JE, Glynn RJ. Blood pressure and risk of developing type 2 diabetes mellitus: The Women’s Health Study. Eur Heart J 2007; 28: 2937–43. PubMedCrossRef
44.
go back to reference Redon J, Olsen MH, Cooper RS, Zurriaga O, Martinez-Beneito MA, Laurent S, et al. Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J 2011: 32:1424-31. PubMedCrossRef Redon J, Olsen MH, Cooper RS, Zurriaga O, Martinez-Beneito MA, Laurent S, et al. Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J 2011: 32:1424-31. PubMedCrossRef
45.
go back to reference Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009; 119: 2146-52. PubMedCrossRef Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009; 119: 2146-52. PubMedCrossRef
46.
go back to reference Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98. CrossRef Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98. CrossRef
47.
go back to reference Abbey M, Owen A, Suzakawa M, Roach P, Nestel PJ. Effects of menopause and hormone replacement therapy on plasma lipids, lipoproteins and LDL-receptor activity. Maturitas 1999; 33: 259–69. PubMedCrossRef Abbey M, Owen A, Suzakawa M, Roach P, Nestel PJ. Effects of menopause and hormone replacement therapy on plasma lipids, lipoproteins and LDL-receptor activity. Maturitas 1999; 33: 259–69. PubMedCrossRef
48.
go back to reference Truong QA, Murphy SA, McCabe CH, Armani A, Cannon CP; on behalf of the timi Study Group. Benefit of intensive statin therapy in women. Results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes 2011; 4; :328-36. PubMedCrossRef Truong QA, Murphy SA, McCabe CH, Armani A, Cannon CP; on behalf of the timi Study Group. Benefit of intensive statin therapy in women. Results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes 2011; 4; :328-36. PubMedCrossRef
49.
go back to reference Harrington C, Horne A, Hasan RK, Blumenthal RS. Statin therapy in primary prevention: new insights regarding women and the elderly. Am J Cardiol 2010; 106: 1357–59. PubMedCrossRef Harrington C, Horne A, Hasan RK, Blumenthal RS. Statin therapy in primary prevention: new insights regarding women and the elderly. Am J Cardiol 2010; 106: 1357–59. PubMedCrossRef
50.
go back to reference Mizuno K, Nakaya N, Ohashi Y, et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women. Analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA-study). Circulation 2008; 117: 494–502. PubMedCrossRef Mizuno K, Nakaya N, Ohashi Y, et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women. Analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA-study). Circulation 2008; 117: 494–502. PubMedCrossRef
51.
go back to reference Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207. PubMedCrossRef Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207. PubMedCrossRef
52.
go back to reference Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitive C-reactive protein or dyslipidemia: results of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010; 121: 1069-77. PubMedCrossRef Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitive C-reactive protein or dyslipidemia: results of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010; 121: 1069-77. PubMedCrossRef
53.
go back to reference Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332; 73–78. PubMedCrossRef Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332; 73–78. PubMedCrossRef
54.
go back to reference De Simone G, Devereux RB, Chinali M, Lee ET, Galloway JM, Barac A, et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J Hypertens 2010; 28: 353–60. PubMedCrossRef De Simone G, Devereux RB, Chinali M, Lee ET, Galloway JM, Barac A, et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J Hypertens 2010; 28: 353–60. PubMedCrossRef
55.
go back to reference Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009; 373 (9677): 1773–79. PubMedCrossRef Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009; 373 (9677): 1773–79. PubMedCrossRef
56.
go back to reference Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008; 121 (suppl 1): S3-S8. PubMedCrossRef Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008; 121 (suppl 1): S3-S8. PubMedCrossRef
57.
go back to reference Gameiro CM, Romao F, Castelo-Branco C. Menopause and aging: changes in the immunesystem. A review. Maturitas 2010; 67: 316–20. PubMedCrossRef Gameiro CM, Romao F, Castelo-Branco C. Menopause and aging: changes in the immunesystem. A review. Maturitas 2010; 67: 316–20. PubMedCrossRef
58.
go back to reference Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology and management of psychosocial risk factors in cardiac practice. J Am Coll Cardiol 2005; 45: 637-51. PubMedCrossRef Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology and management of psychosocial risk factors in cardiac practice. J Am Coll Cardiol 2005; 45: 637-51. PubMedCrossRef
59.
go back to reference Low CA, Thurston RC, Matthews KA. Psychosocial factors in the development of heart disease in women: Current Research and Future Directions. Psychosom Med 2010; 72: 842–54. PubMedCrossRef Low CA, Thurston RC, Matthews KA. Psychosocial factors in the development of heart disease in women: Current Research and Future Directions. Psychosom Med 2010; 72: 842–54. PubMedCrossRef
60.
go back to reference Chow CK, Islam S, Bautista L, Rumboldt Z, Yusufali A, Xie C, et al. Parental history and myocardial infarction risk across the world. J Am Coll Cardiol 2011; 57: 619–27. PubMedCrossRef Chow CK, Islam S, Bautista L, Rumboldt Z, Yusufali A, Xie C, et al. Parental history and myocardial infarction risk across the world. J Am Coll Cardiol 2011; 57: 619–27. PubMedCrossRef
61.
go back to reference Steegers EAP, Dadelszen P von, Duvkot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010; 376(9741): 631-44. PubMedCrossRef Steegers EAP, Dadelszen P von, Duvkot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010; 376(9741): 631-44. PubMedCrossRef
62.
go back to reference Oertelt-Prigione S, Regitz-Zagrosek V. Gender aspects in cardiovascular pharmacology. J of Cardiovasc Trans Res 2009; 2: 258–66. CrossRef Oertelt-Prigione S, Regitz-Zagrosek V. Gender aspects in cardiovascular pharmacology. J of Cardiovasc Trans Res 2009; 2: 258–66. CrossRef
63.
go back to reference Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352(13); 1293-1304. PubMedCrossRef Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352(13); 1293-1304. PubMedCrossRef
64.
go back to reference Baroletti S, Dell’Orfano H. Medication adherence in cardiovascular disease. Circulation 2010; 121: 1455–58. PubMedCrossRef Baroletti S, Dell’Orfano H. Medication adherence in cardiovascular disease. Circulation 2010; 121: 1455–58. PubMedCrossRef
Metagegevens
Titel
Cardiovasculair Risicomanagement Bij Vrouwen
Auteurs
Dr. Angela Maas
Dr. Ed De Kluiver
Prof. Dr. Toine Lagro-Janssen
Copyright
2011
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-8782-3_6